secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2023-04-24T23:59:59+00:00
Accession:  0001104659-23-049060
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance appoints Wendy L. Yarno to Board; Wendy L. Dixon not standing for re-election
--------------------------------------------------------------------------------

- Wendy L. Yarno appointed as director effective April 18, 2023; previously EVP & CMO at Merck over 26 years.
- Wendy L. Dixon will not stand for re-election at June 2023 annual meeting; will serve until meeting ends.
- Board increased from 7 to 8 members for Yarno's seat; will reduce back to 7 after annual meeting.
- Yarno granted standard deferred restricted stock unit per new-director compensation; no related-party transactions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465923049060/0001104659-23-049060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465923049060/tm2313552d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-049060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer